The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor

Molecular Pharmacology

Volumn 79, Issue 5, 2011, Pages 855-865

  Leach, Katie ^a   Davey, Anna E ^a   Felder, Christian C ^b   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 5 CHLORO 6 METHOXY 4 METHYL THIENO[2,3 BIS]PYRIDINE 2 CARBOXYLIC ACID CYCLOPROPYLAMIDE; AMINO ACID; CHOLINERGIC RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; LY 2033298; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STIMULUS RESPONSE; TRANSMEMBRANE DOMAIN 3;

ALLOSTERIC SITE; AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MUSCARINIC AGONISTS; MUTAGENESIS, SITE-DIRECTED; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M4;

EID: 79954987479     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.070938     Document Type: Article

References (40)

1. Altenbach C, Yang K, Farrens DL, Farahbakhsh ZT, Khorana HG, and Hubbell WL (1996) Structural features and light-dependent changes in the cytoplasmic inter-helical E-F loop region of rhodopsin: a site-directed spin-labeling study. Biochemistry 35:12470-12478. (Pubitemid 26318042)
2. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162. (Pubitemid 14217337)
3. Burstein ES, Spalding TA, and Brann MR (1998) The second intracellular loop of the m5 muscarinic receptor is the switch which enables G-protein coupling. J Biol Chem 273:24322-24327. (Pubitemid 28454919)
4. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christo-poulos A, Lazareno S, Birdsall NJ, Bymaster FP, et al. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978-10983.
5. Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19:351-357. (Pubitemid 29011723)
6. Conn PJ, Jones CK, and Lindsley CW (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30:148-155.
7. Curtis CA, Wheatley M, Bansal S, Birdsall NJ, Eveleigh P, Pedder EK, Poyner D, and Hulme EC (1989) Propylbenzilylcholine mustard labels an acidic residue in transmembrane helix 3 of the muscarinic receptor. J Biol Chem 264:489-495. (Pubitemid 19027630)
8. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
9. Elling CE, Thirstrup K, Holst B, and Schwartz TW (1999) Conversion of agonist site to metal-ion chelator site in the beta (2)-adrenergic receptor. Proc Natl Acad Sci USA 96:12322-12327. (Pubitemid 29513500)
10. Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodop-sin. Science 274:768-770. (Pubitemid 26398253)
11. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, and Kobilka BK (1997) Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J 16:6737-6747. (Pubitemid 27503486)
12. Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285:7459-7474.
13. Han SJ, Hamdan FF, Kim SK, Jacobson KA, Bloodworth LM, Li B, and Wess J (2005) Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M (3) muscarinic acetylcholine receptor. J Biol Chem 280:34849-34858. (Pubitemid 41504619)
14. Hopkins AL and Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727-730. (Pubitemid 37361545)
15. Huang XP, Prilla S, Mohr K, and Ellis J (2005) Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis (ammonio) alkane-type hexamethylene-bis-[dimethyl-(3- phthalimidopropyl) am-monium]dibromide. Mol Pharmacol 68:769-778. (Pubitemid 41206031)
16. Hubbell WL, Altenbach C, Hubbell CM, and Khorana HG (2003) Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv Protein Chem 63:243-290. (Pubitemid 36268430)
17. Hulme EC, Lu ZL, Bee M, Curtis CA, and Saldanha J (2001) The conformational switch in muscarinic acetylcholine receptors. Life Sci 68:2495-2500. (Pubitemid 32455687)
18. Hulme EC, Lu ZL, Saldanha JW, and Bee MS (2003) Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 31:29-34. (Pubitemid 36241392)
19. Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, and Gether U (2001) Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 276:9279-9290.
20. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, et al. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28:10422-10433.
21. Kurtenbach E, Curtis CA, Pedder EK, Aitken A, Harris AC, and Hulme EC (1990) Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. J Biol Chem 265:13702-13708.
22. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
23. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, and Christopoulos A (2010) Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential anti-psychotic properties. Neuropsychopharmacology 35:855-869.
24. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28:382-389. (Pubitemid 47087967)
25. Lebon G, Langmead CJ, Tehan BG, and Hulme EC (2009) Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcho-line receptors. Mol Pharmacol 75:331-341.
26. Lodowski DT, Angel TE, and Palczewski K (2009) Comparative analysis of GPCR crystal structures. Photochem Photobiol 85:425-430.
27. Lu ZL, Curtis CA, Jones PG, Pavia J, and Hulme EC (1997) The role of the aspartate-arginine-tyrosine triad in the m1 muscarinic receptor: mutations of aspartate 122 and tyrosine 124 decrease receptor expression but do not abolish signaling. Mol Pharmacol 51:234-241. (Pubitemid 27074144)
28. Matsui H, Lazareno S, and Birdsall NJ (1995) Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 47:88-98.
29. May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, and Chris-topoulos A (2007a) Structure-function studies of allosteric agonism at M2 musca-rinic acetylcholine receptors. Mol Pharmacol 72:463-476. (Pubitemid 47124126)
30. May LT, Leach K, Sexton PM, and Christopoulos A (2007b) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51. (Pubitemid 46277033)
31. Motulsky H and Christopoulos A (2004) Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting. Oxford University Press, New York.
32. Nawaratne V, Leach K, Felder CC, Sexton PM, and Christopoulos A (2010) Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 285:19012-19021.
33. Nawaratne V, Leach K, Suratman N, Loiacono RE, Felder CC, Armbruster BN, Roth BL, Sexton PM, and Christopoulos A (2008) New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol 74:1119-1131.
34. Prilla S, Schrobang J, Ellis J, Höltje HD, and Mohr K (2006) Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol Pharmacol 70:181-193.
35. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, and Elling CE (2006) Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu Rev Pharmacol Toxicol 46:481-519. (Pubitemid 43271198)
36. Spalding TA, Birdsall NJ, Curtis CA, and Hulme EC (1994) Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors. J Biol Chem 269:4092-4097. (Pubitemid 24237760)
37. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, and Conn PJ (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679. (Pubitemid 37444798)
38. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, and Christo-poulos A (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283:29312-29321.
39. Voigtländer U, Jöhren K, Mohr M, Raasch A, Tränkle C, Buller S, Ellis J, Höltje HD, and Mohr K (2003) Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol Pharmacol 64:21-31. (Pubitemid 36759814)
40. Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, and Kobilka B (2006) Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol 2:417-422. (Pubitemid 44114919)